Skip to main content
  • Policy
    Get Involved
    Watch Best of BIO
    Advocacy Toolkit
    BIOAction
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    Agriculture & Environment
    Food and Farm Innovation
    Sustainable Fuels
    Biobased Manufacturing
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Join Today
    Member Directory
    Have a Voice
    Membership Eligibility
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member ag&evnt
    Agriculture & Environment
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    BIO Business Solutions
    Join Today
  • News & Insights
    Latest blogs on BIOtechNOW
    Watch Best of BIO
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    Good Day BIO
    I AM BIO Podcast
    All News & Insights

    Sign up for the Good Day BIO Newsletter >

  • BIOEquality
    1. Promote

    Health equality in access to medicines and ensuring diversity in clinical trials.

    2. Invest

    In the current and next generation of black scientists and entrepreneurs.

    3. Expand

    Opportunities for women, Black and other minority populations in the growing Bio-economy.

    The Right Mix Matters

    Providing tools to accelerate gender, racial, ethnic and LGBTQ representation on biotech company boards, in C-suites and in functional leadership positions.

  • Events
    Event Portfolio
    Business Development
    Health
    Agriculture & Environment
    International
    Members Only
    All Events
    BIO Digital 2021

    June 10-18

    New extended dates for the world’s largest biotech partnering event

    Subscribe for Updates
    Evt Bif MegaMenu
    BIO Investor Forum Digital

    October 19-20, 2021
    Watch the Best of BIO Sessions

    BIO Partnering @ JPM
    BIO Patient & Health Advocacy Digital Summit

    October 27-28, 2021

    Evt CEO MegaMenu
    BIO CEO & Investor Digital Conference

    Watch the Best Sessions Now >

    BIO Online Learning

    BIO now offers on-demand online classes that can be taken anywhere, anytime and at your own pace. BIO Member and group discounts available!

  • About
    About Us
    Learn about our mission, vision, values and priorities
    Programs & Initiatives
    Find out about BIO's programs & initiatives
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • How Do I
    How Do I?

    Connect with BIO to save money, meet partners and expand your influence by promoting your company and joining our advocacy efforts. Join to get started today!

    Shape Policy
    Save Money
    Meet Partners
    Promote
    Get Started
    Join Today
  • Search
Logo
Logo
Home
Search
  • Human Health
  • Agriculture & Environment
  • Business & Bio Industry
  • Policy & Regulatory
  • International Issues
  • Network & Partnering
  • Events
Logo
Logo
Search
Explore the Blog
  • Human Health
  • Agriculture & Environment
  • Business & Bio Industry
  • Policy & Regulatory
  • International Issues
  • Network & Partnering
  • Events
682 Results Found

BTN-MTC_Researchers-DNA-364x210
New Approaches to Reimbursement for Gene Therapy: What Can We Learn from Models Currently in Practice?
It’s obvious that cost presents a major burden for patient access to gene therapy. The recent approval of Novartis’ gene therapy Zolgensma, which treats children under two with spinal muscular atrophy (SMA), was quickly overshadowed by criticism about the drug’s $2.125 million price tag. As the…

Pharmacy counter
Why Concerns About a “Break Down” in Drug Pricing Are Misplaced
Just moments after it was announced the FDA had approved a new treatment for spinal muscular atrophy, Dr. Peter Bach was warning about a “break down” in the U.S. drug pricing system. It’s unfortunate Dr. Bach would respond to the discovery of a miracle cure for a fatal disease with such doom and…

Hands putting a drop of liquid substance into a tube
Important Perspectives on Innovation and Costs
This is an exciting time in biomedical innovation. New and highly innovative therapies are coming to market that promise significant improvements in patient health. They include a range of novel approaches to treating disease, like gene therapy, immunotherapy, and RNA interference. Many of the most…

Pharmacy counter
“Health Care’s Big Spending Mismatch”
This week, Axios reported on new data that shows “the health care services that rack up the highest out-of-pocket costs for patients aren't the same ones that cost the most to the health care system overall.” While hospital care eats up the lion’s share of health care spending—a staggering $1.1…

Hands putting a drop of liquid substance into a tube
Setting the Record Straight on March-In Rights
In a recent piece for The Washington Post, author Christopher Rowland inaccurately suggested that the federal government has the power to effectively impose price controls over products that have a link to federally-funded research through its patent “march-in” rights under the Bayh-Dole…

Rows of pharmaceutical drugs
WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices
This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in Florida to import prescription drugs from Canada. But as the writers warn, such a move would be “impractical, unsafe and unlikely” to reduce prices for patients and consumers at the pharmacy counter. “When…

Gavel sitting on top of a book that reads PATENT LAW
When Intervention Stifles Innovation
Dr. Gregory Dolin of the Center for Medicine and Law at the University of Baltimore School of Law shared his objections to legislative proposals that falsely link drug costs with patents in an op-ed that ran in The Washington Times this week. As Dolin states, current legislative proposals would…

Woman speaking to pharmacist
Greenwood: In Pharma Value Chain, PBMs Manage to Benefit
Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance Committee for calling on pharmacy benefit managers (PBMs) to testify before Congress but also warned of their deceptive tactics aimed to bolster their bottom-lines. “PBMs were originally…

Pharmacy counter
A Few Questions as PBMs Have Their Day on Capitol Hill
Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in the drug cost ecosystem. For years, these Fortune 100 companies largely escaped scrutiny for their role in deciding what patients pay out of pocket for medicines, but that’s finally starting to…

Rows of pharmaceutical drugs
Dr. Emanuel Misses the Mark with Latest Industry Attack
Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when it seeks to explain the cost of prescription drugs. But in making this claim, Dr. Emanuel is guilty of engaging in some of his own acts of deception. For starters, drug prices are not …

Pagination

  • « « First
  • ‹ ‹‹
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • › ››
  • » Last »
Explore BIO
Policy
Events
Industry Insights
About
Join Now
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Digital
BIO CEO & Investor Conference
BIO Investor Forum Digital
BIO IMPACT Digital
BIO Online Learning
BIO DOUBLE HELIX SPONSORS
Eli Lilly and Company
Amgen
Bristol Myers Squibb
Genentech Logo
Johnson & Johnson Logo
Merck
MSD
BIO HELIX SPONSORS
Pfizer Inc logo
Sanofi Logo
AbbVie Logo
1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2021 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO